ArticleJournal of neuro-oncology2022

High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors.

Andrew B DeAtkine et al.PubMed ↗Publisher ↗

No numbers read from the abstract.